The Best Steward May Be a Different Owner: What Linerixibat Teaches Us About Strategy
What an IBAT inhibitor, a successful Phase III program, and a global licensing agreement can teach us about strategic alignment and portfolio stewardship.
AI Won Round One. The Hardest Problem Is Still Ahead
How systems biology and network medicine may help solve the biggest challenge in drug discovery: human biology. When I was studying pharmacokinetics between 2005 and 2010, the field was hitting its stride. Lipinski’s Rule of Five had already reshaped how medicinal chemists thought about drug-likeness. Population PK modeling and early PBPK tools like Simcyp were […]